PD-L1 Assay Concordance in Metastatic Renal Cell Carcinoma and Metastatic Urothelial Carcinoma.

Autor: Brown LC; Department of Medicine, School of Medicine, Duke University, Durham, NC; Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, NC., Zhu J; Department of Medicine, School of Medicine, Duke University, Durham, NC; Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, NC., Labriola MK; Department of Medicine, School of Medicine, Duke University, Durham, NC; Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, NC., Wu Y; Department of Biostatistics and Bioinformatics, School of Medicine, Duke University, Durham, NC., Cheris S; Department of Pathology, School of Medicine, Duke University, Durham, NC., Liu X; Department of Pathology, School of Medicine, Duke University, Durham, NC., Perkinson K; Department of Pathology, School of Medicine, Duke University, Durham, NC., Su Z; Department of Pathology, School of Medicine, Duke University, Durham, NC., McCall S; Department of Pathology, School of Medicine, Duke University, Durham, NC., Huang J; Department of Pathology, School of Medicine, Duke University, Durham, NC., Foo WC; Department of Pathology, School of Medicine, Duke University, Durham, NC., Gupta RT; Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, NC; Department of Radiology, School of Medicine, Duke University, Durham, NC., Armstrong AJ; Department of Medicine, School of Medicine, Duke University, Durham, NC; Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, NC., George DJ; Department of Medicine, School of Medicine, Duke University, Durham, NC; Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, NC., Harrison MR; Department of Medicine, School of Medicine, Duke University, Durham, NC; Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, NC., Zhang T; Department of Medicine, School of Medicine, Duke University, Durham, NC; Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, NC. Electronic address: tian.zhang2@duke.edu.
Jazyk: angličtina
Zdroj: Clinical genitourinary cancer [Clin Genitourin Cancer] 2020 Dec; Vol. 18 (6), pp. 509-513. Date of Electronic Publication: 2020 Apr 10.
DOI: 10.1016/j.clgc.2020.03.020
Abstrakt: Background: Immune checkpoint inhibitors are now standard of care for many patients with metastatic renal cell carcinoma (mRCC) and metastatic urothelial carcinoma (mUC). Given real-world limitations in programmed death-ligand 1 (PD-L1) testing, concordance studies between PD-L1 assays are needed. We undertook comparisons of Dako 28-8 and Ventana SP142 assays in mRCC and Dako 22C3 and Ventana SP263 assays in mUC.
Patients and Methods: Thirty-two patients with mRCC and 18 patients with mUC who had received immune checkpoint inhibitor therapy were identified. Formalin-fixed paraffin-embedded tumor samples for patients with mRCC were evaluated with Dako 28-8 and Ventana SP142 PD-L1 immunohistochemistry assays. For patients with mUC, formalin-fixed paraffin-embedded tumor samples were evaluated with Dako 22C3 and Ventana SP263 PD-L1 immunohistochemistry assays.
Results: The majority (29/32; 91%) of mRCC cases were concordant between assays. The majority (17/18; 94%) of mUC cases were also concordant between assays.
Conclusions: There was strong concordance between PD-L1 assays chosen for comparison in both mRCC and mUC, with similar performance characteristics. One limitation is the small number of cases in this study; larger comparison studies are needed for this biomarker in mRCC and mUC.
(Copyright © 2020 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: